Man Group plc Invests $1.46 Million in Aquestive Therapeutics, Inc. $AQST

Man Group plc bought a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 351,700 shares of the company’s stock, valued at approximately $1,463,000.

Several other institutional investors and hedge funds have also modified their holdings of AQST. AWM Investment Company Inc. bought a new position in Aquestive Therapeutics during the second quarter worth about $1,978,000. Legal & General Group Plc bought a new position in shares of Aquestive Therapeutics during the second quarter worth approximately $44,000. The Manufacturers Life Insurance Company bought a new position in shares of Aquestive Therapeutics during the second quarter worth approximately $122,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $42,000. Finally, Quantbot Technologies LP bought a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $99,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Trading Up 2.7%

Shares of NASDAQ:AQST opened at $5.38 on Thursday. The firm has a 50 day moving average of $4.26 and a 200-day moving average of $4.19. The stock has a market capitalization of $675.24 million, a PE ratio of -8.28 and a beta of 1.48. Aquestive Therapeutics, Inc. has a 12 month low of $2.93 and a 12 month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million for the quarter, compared to the consensus estimate of $11.42 million. On average, research analysts predict that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current fiscal year.

Insider Buying and Selling

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the sale, the director directly owned 25,000 shares in the company, valued at $125,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Wall Street Zen lowered Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Aquestive Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.80.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.